Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 3 | BMC Medicine

Fig. 3

From: Modest heterologous protection after Plasmodium falciparum sporozoite immunization: a double-blind randomized controlled clinical trial

Fig. 3

Neutralizing effect of CPS-induced antibodies on in vitro sporozoite functionality of homologous and heterologous P. falciparum strains. (a) The number of primary human hepatocytes infected by homologous NF54 sporozoites in the presence of pre- or post-immunization plasma in all (n = 24) CPS-immunized volunteers was determined by microscopy. (b) P. falciparum NF54, NF135.C10, or NF166.C8 sporozoites were pre-incubated with pre- or post-immunization plasma from CPS-immunized volunteers and the percent inhibition of intra-hepatic development of NF54, NF135.C10, or NF166.C8 was calculated for post- compared to pre-immunization plasma for each individual volunteer and presented as squares (NF135.C10), triangles (NF166.C8), or circles (NF54). Data are shown as the mean of triplicate measurements for each individual volunteer (a) or the median of all data points with an interquartile range (b). Differences in the percent inhibition of intra-hepatic development between parasite strains were tested using one-way ANOVA with Bonferroni’s multiple comparison correction

Back to article page